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common TCF7L2 polymorphisms and 
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ABSTRACT
Objective: The global burden of diabetes mellitus will impact strongly American countries in the 
coming decades. Type 2 diabetes mellitus (T2DM) is a multifactorial disease and the basis for its gene-
tic susceptibility remains not fully understood. Different population studies have demonstrated that 
variants of the TCF7L2 gene are strongly associated with an increased risk of T2DM. Moreover, insti-
tutions or countries with limited budget to conduct genetic research need cost effective methods for 
detecting DNA variants. Subjects and methods: We standardized a rapid and simple allele-specific 
PCR method for genotyping the rs12255372 single nucleotide polymorphism (SNP) in a pilot study 
exploring the association of three TCF7L2 polymorphisms (rs7903146, rs12255372 and DG10S478) 
with T2DM in 70 patients and 73 controls from Venezuela. Results: The performance of the designed 
allele-specific PCR reaction for rs12255372 genotyping was reliable and accurate. Patients carrying 
the TCF7L2 rs7903146 T allele (CT + TT genotypes) and heterozygous CT genotype had a significantly 
higher risk for T2DM (OR = 2.9 and 2.3, respectively). Although rs12255372 and DG10S478 risk alleles 
predominated in T2DM group no statistical significance was found. Conclusions: We developed a 
novel allele-specific PCR method for easier and rapid detection of rs12255372 polymorphism without 
the use of expensive instrumentation and reagents. Our study in a relatively small sample of the 
Venezuelan population replicated the association of the rs7903146 SNP with T2DM. Further studies 
with larger sample size and more biochemical data should be conducted to explore the genetic basis 
of T2DM susceptibility in Venezuela. Arch Endocrinol Metab. 2016;60(3):246-51
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INTRODUCTION
D iabetes mellitus is an endocrine disorder charac-terized by dysregulation of insulin production, 
insulin sensitivity, and glucose control. Diabetes is ge-
nerally classified in type 1 diabetes mellitus (T1DM), 
which consists of an autoimmune etiology, and T2DM, 
which includes a heterogeneous group of metabolic di-
sorders characterized by the inability of pancreatic beta 
cells to increase insulin secretion in order to compen-
sate for insulin resistance (1). T2DM patients are typi-
cally diagnosed in adulthood and usually after the age 
of 40. T2DM is the most common form of diabetes, 
accounting for 90% of cases in the world (1). The bur-
den of T2DM is growing worldwide with near 80% of 
patients living in low- and middle-income countries (2). 
By 2035 the number of people with diabetes in South 
and Central America will increase by 60% (2). Moreo-
ver, in Venezuela, T2DM was ranked as the fifth lea-
ding cause of mortality in 2011 (3). 
The development of T2DM results from interaction 
between environmental factors and a robust genetic 
component (4). These environmental factors, inclu-
ding obesity, sedentary lifestyle, small or large birth 
weight and stress (5), do not influence everyone in 
the same way, which highlights the role that genetic 
susceptibility plays in the etiology and manifestation of 
T2DM. Multiple T2DM risk genes were initially iden-
tified using candidate gene and linkage-based studies, 
and more recently by genome-wide association studies 
(GWAS) (reviewed at 6,7). 
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TCF7L2 (transcription factor 7-like 2) is among the 
highly replicated genes showing robust association with 
T2DM (8,9). The TCF7L2 gene spans 215.9 kb on 
chromosome 10q25.3, and its product is a high-mobi-
lity box-containing transcription factor involved in the 
Wnt signaling pathway (10). Wnt pathway activity plays 
an important role for lipid and glucose metabolism, 
pancreatic islets proliferation, regeneration and func-
tion, and for production of the insulinotropic hormone 
glucagon-like peptide 1 (GLP-1) (11-13). Therefore, 
alteration in this pathway could cause the reduction of 
GLP-1 secretion, then affecting insulin secretion, and 
subsequently, among other effects, impairing blood 
glucose homeostasis. 
After the initial report on the association of a 
common microsatellite within intron 3 of TCF7L2 
(DG10S478) with T2DM (14), successive replication 
studies conducted in populations of different ethnic ori-
gin confirmed the strong association between a number 
of TCF7L2 polymorphisms, especially rs7903146 and 
rs12255372, and T2DM (15-22). Moreover, among 
Latin American countries there are only reports on the 
association of TCF7L2 polymorphisms and T2DM from 
Colombia (23), Brazil (24-28) and Mexico (9,29-32). 
Latin American populations are characterized by high 
socioeconomic and genetic heterogeneity with varying 
degrees of ancestral population proportions from coun-
try to country, thus more studies are needed exploring 
the basis of T2DM susceptibility from these mixed po-
pulations. 
Most commonly used methods for detecting DNA 
polymorphisms are restriction enzyme digestion based. 
However, they generally require 2 days to complete en-
tire procedure. Sequencing or real-time PCR systems are 
the alternative, but they are costly. Therefore, we used 
PCR assays for rapid and simple genotyping in a pilot stu-
dy to explore the role of TCF7L2 gene polymorphisms 
(rs7903146, rs12255372 and DG10S478) in conferring 
susceptibility to T2DM in the Venezuelan population. 
For this purpose, we designed an allelic-specific PCR re-
action for genotyping the rs12255372 (G/T) SNP, thus 
providing a simple, reproducible and low-cost assay. 
SUBJECTS AND METHODS 
Subjects
The patient population consists of 70 subjects with 
T2DM (31 men and 39 women), while the control 
group included 73 non-diabetic subjects (25 men and 
48 women) randomly selected from the general popu-
lation. We collected all blood samples at the Hospital 
Antonio María Pineda (HAMP), Barquisimeto, Vene-
zuela.
Patient group consisted of subjects with diagnosis of 
Diabetes (defined according to the American Diabetes 
Association criteria) made at least two years before en-
tering the study, who were on drug treatment for the 
disease. Subjects who met inclusion criteria were en-
rolled into the control group: age at examination over 
40 years, absence of family history of diabetes in the 
previous two generations and fasting plasma glucose of 
less than 110 mg/dL (6.1 mmol/l). Anthropometric 
measurements including weight, height, and waist cir-
cumference (WC) were obtained using standardized te-
chniques. The body mass index (BMI) was calculated as 
the weight in kilograms divided by the square of height 
in meters (kg/m2).
The study was approved by the Bioethics Com-
mittee of the School of Health Sciences, Universidad 
Centroccidental Lisandro Alvarado (UCLA), and per-
formed in accordance with the Declaration of Helsinki. 
Informed consent was obtained from each patient be-
fore participation in the study. 
Genotyping
Peripheral blood samples of patient and control groups 
were collected in EDTA-anticoagulated tubes, and 
then DNA was extracted using Wizard® Genomic 
DNA Purification kit (Promega). DNA concentration 
was checked by UV absorption at 260 and 280 nm. 
All amplification reactions were carried out on a Gene-
Amp® PCR System 9700 (Applied Biosystems) thermo 
cycler. Specific PCR reactions were conducted in a final 
volume of 25 µl containing 1X Green GoTaq® Flexi 
Buffer, 0.2 mM dNTPs, 1.5 mM MgCl2, 1.25 U of 
GoTaq DNA Polymerase (Promega) and 20-50 ng of 
genomic DNA.
Primers used in PCR reactions carried out in this 
work are shown in table 1. We designed an allele-speci-
fic PCR reaction for genotyping the rs12255372 SNP. 
For this reaction we designed two doubly mismatched 
reverse primers with mismatches in their last 3’ nucle-
otide and at the third nucleotide from the 3’ end such 
that allow to specifically amplify one of the two variants 
(G/T) of the rs12255372 polymorphism. Briefly, for 
each sample, two PCR reactions were run in parallel, 
combining a common forward primer (CFw) and one 
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of the two reverse primers in order to detect the presen-
ce of the polymorphic base (Rev_G and Rev_T). The 
observation of a 160-bp band in PCR reaction G or 
T indicated the presence of the respective allele. PCR 
reactions contained 0.3 µM of each primer and the 
cycling conditions were as follows: initial denaturation 
for 3 min at 95 °C; followed by 35 cycles of 20 s at 
95 °C, 30 s at 60 °C, and 30 s at 72 °C; then a final 
extension for 5 min at 72 °C. PCR products were elec-
trophoresed on 3% agarose gels.
We conducted the rs7903146 genotype assays by an 
allele-specific PCR reaction using primers and cycling 
conditions previously reported by Dutra and cols. (33). 
We used primers described by Grant and cols. (14) at 
an annealing temperature of 62 °C to amplify microsa-
tellite DG10S478, then the PCR products were sepa-
rated by electrophoresis on a 3% w/v agarose gel for 
allele detection using the nomenclature proposed by 
these authors: allele 0 (384-bp) is the smallest and all 
the other are included in a composite allele which is 
referred to as allele X.
We used the Kodak 1D Molecular Imaging Softwa-
re (Eastman Kodak, Rochester, NY) for image analysis 
of ethidium bromide-stained agarose gels and for allelic 
assignment of the PCR products and restrictions frag-
ments.
Statistical analysis
Genotype frequencies were examined for deviations 
from their corresponding Hardy-Weinberg equilibrium 
using Arlequin ver. 2.000 software. SPSS software, ver-
sion 14.0, was used for the rest of statistical analyses. 
Mean age of cases and controls, fasting plasma glucose, 
BMI and WC were compared by t test. The significance 
of the differences in the distribution of the polymor-
phisms was calculated using the χ2 or Fisher’s exact test. 
Association between genotypes and T2D was tested by 
logistic regression. A P value of < 0.05 was considered 
to be significant.
RESULTS
Table 2 shows clinical and biochemical characteristics of 
the study subjects. Comparison between groups showed 
that the fasting plasma glucose levels were significantly 
higher in the diabetic subjects, while mean age, BMI 
and WC were similar in both groups (P > 0.05). The ge-
notypic distribution in both the control and the T2DM 
groups was in Hardy-Weinberg equilibrium.
We were able to genotype all the samples inclu-
ded in the study with the performed PCR reactions. 
We used the PCR-RFLP protocol described by Bodhi-
ni and cols. (18) to demonstrate the accuracy of our 
allele-specific PCR reaction for the genotype discrimi-
nation of rs12255372 polymorphism. As expected, the 
combination of the two reverse primers with a single 
forward primer in separated reactions, allowed the spe-
cific amplification of each one of the alleles (G/T) of 
the rs12255372 polymorphism (Figure 1). 
Table 3 shows allele and genotype frequencies of 
the TCF7L2 polymorphisms. The presence of the 
TCF7L2 rs7903146 T allele (CT + TT genotypes) and 
heterozygous CT genotype was associated with higher 
diabetes risk (OR = 2.9 and 2.3, respectively). The dis-
tribution of rs12255372 and DG10S478 polymorphis-
ms showed no significant difference between the two 
groups, despite the homozygote genotypes and the 
carriers for the mutant alleles (T for rs12255372 and X 
for DG10S478) predominated in T2DM patients (Ta-
ble 3). None of the polymorphisms showed significant 
correlation with fasting plasma glucose, BMI or WC in 
either the control or the diabetic subjects. Moreover, 
haplotypes constructed using the three polymorphisms 
were not significantly associated with T2DM risk.
Table 1. Primers used in this work for TCF7L2 polymorphisms genotyping
Polimorfism Primer Sequence (5’ → 3’) Detection Origin
rs7903146 C/T rs7903146 C: GAACAATTAGAGAGCTAAGCACTTTTTAGAAAC
rs7903146 T: GAACAATTAGAGAGCTAAGCACTTTTTAGAGAT
rs7903146 R: AGATGAAATGTAGCAGTGAAGTGC
Allele-specific PCR Dutra and cols. (33)
rs12255372 G/T CFw: CTGGAAACTAAGGCGTGAGGGA
Rev_G: CAGAGGCCTGAGTAATTATCAGAATATGATC
Rev_T: CAGAGGCCTGAGTAATTATCAGAATATGCTA
Allele-specific PCR This work
DG10S478 STR Fw: TTCAGGCCATTGGTGTTGTA
Rev: AAAGTTCCCACCATCCCACT
PCR Grant and cols. (14)
Bold underlined bases indicate a mismatch for increasing PCR specificity. Nucleotides at 3’ end (indicated as bold cursive case) are specific for each one of the rs12255372 alleles (G/T).
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Table 2. Characteristics of the normal and diabetic study subjects
Controls
n = 73
T2D cases
n = 70 P value
Age (years) 50.8 ± 8.5.5 53.9 ± 10.5 0.055
WC (cm) 91.8 ± 12.6 91.9 ± 10.9 0.740
BMI (kg/m2) 27.0 ± 4.9 26.8 ± 4.8 0.867
Fasting plasma glucose (mg/dL) 97.0 ± 7.7 179.7 ± 87.1 0.000
Table 3. Genotype distribution of the TCF7L2 rs7903146, rs12255372 and DG10S478 polymorphisms in controls and T2DM patients from Venezuela
Marker
Controls
n = 73
T2D cases
n = 70 P value OR (%95 CI)
n (%) n (%)
rs7903146
CC 46 (63.0) 26 (37.1) 0.002 0.3 (0.18–0.68)
CT 22 (30.1) 35 (50.0) 0.015 2.3 (1.17–4.60)
TT 5 (6.8) 9 (12.9) 0.227 2.0 (0.64–6.32)
TT + CT 27 (37.0) 44 (62.9) 0.002 2.9 (1.46–5.69)
rs12255372
GG 46 (63.0) 33 (47.1) 0.056 0.5 (0.27–1.02)
GT 24 (32.9) 29 (41.4) 0.290 1.4 (0.73–2.86)
TT 3 (4.1) 8 (11.4) 0.101  3.0 (0.77–11.85)
TT + GT 27 (37.0) 37 (52.9) 0.056 1.9 (0.98–3.73)
DG10S478
0/0 47 (64.4) 39 (55.7) 0.290 0.7 (0.34–1.36)
0/X 23 (31.5) 24 (34.3) 0.724 1.1 (0.56–2.28)
X/X 3 (4.2) 7 (10.0) 0.174  2.6 (0.63–10.31)
X/X + 0/X 26 (35.6) 31 (44.3) 0.290 1.4 (0.73–2.81)
Figure 1. Genotyping of the TCF7L2 rs12255372 (G/T) polymorphism by 
an allele-specific PCR assay. For each sample, two PCR reactions were 
performed, each including a common forward primer and rs12255372 G 
(reaction G) or rs12255372 T (reaction T) reverse primer, according to the 
allele to be amplified. A 160-bp DNA fragment indicated the presence of 
the allele, while amplification failure indicated the absence of the allele in 
the sample. In a 3% w/v agarose gel, MW indicates molecular size 
standard, G and T indicate the product from reaction G and reaction T, 
respectively, amplified from selected DNA sample of each possible 
genotypes (GG, GT and TT) and H
2
O (negative control).
DISCUSSION
According to the Global Burden of Disease report, the 
prevalence of T2DM will have an increasing and the 
highest impact on the health systems and society in Lat-
in America countries (34). Moreover, years of potential 
life lost rates due to diabetes among adults are more 
concentrated in Oceania, Latin America, North Africa, 
and the Middle East (35). Therefore, among other ef-
forts necessary for the prevention and treatment of dia-
betes in Latin American countries, identifying of spe-
cific genetic markers and/or validates those examined 
in multiple ethnicities for better prediction of T2DM 
risk for our mixed populations is essential.
Grant and cols. (14), when reported the associa-
tion of the STR DG10S478 of TCF7L2 with T2DM 
in white patients from several populations, found that 
the rs12255372 and rs7903146 SNPs were in strong 
linkage disequilibrium with the microsatellite and sho-
wing similarly robust associations with disease. These 
and other authors have recommended that these two 
SNPs should be genotyped in all attempts at replica-
tion (14,36). Moreover, numerous studies and meta-
-analyses examining various ethnic groups demonstra-
ted an association between TCF7L2 SNPs and T2DM 
and, although with some inconsistent results, the two 
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most highly correlated are rs7903146 and rs12255372 
(36-38).
Herein, we observed that subjects harboring 
CT genotype and carriers of the allele T of TCF7L2 
rs7903146 SNP had a higher T2DM risk (OR = 2.9 
and 2.3, respectively). Similarly, this polymorphism was 
found associated with diabetes in several works carried 
out in admixed populations from other Latin Ameri-
can countries (9,23-25,28,29,31,32). However, Barros 
and cols. (27) failed to find an association of this variant 
with T2DM in northeastern populations from Brazil; 
while, Parra and cols. (30) also reported no association 
between the rs7903146 SNPs and T2DM in a replicate 
case-control study conducted in Mexico City. 
In our study, although the frequency of known risk 
alleles of rs12255372 and DG10S478 polymorphisms 
was higher in T2DM patients, the association with di-
sease was not strong. Similarly, Furgeri and cols. (26) 
and Barros and cols. (27) did not find association of the 
TCF7L2 rs12255372 SNP with T2DM in Brazilian po-
pulations. Moreover, Franco and cols. (39) found that 
TCF7L2 rs7903146 and rs12255372 variants did not 
make major contributions to the incidence of glucose 
tolerance abnormalities in Japanese-Brazilians, a popu-
lation with a high prevalence of T2DM. Finally, recent 
large meta-analyses confirmed that the rs12255372 
SNP is significantly associated with susceptibility to 
T2DM in the global population, although in some eth-
nic populations, no significant associations were found 
(36,38,40).
Although the precise role of TCF7L2 with regard 
to T2DM risk is still under investigation, evidence sug-
gests that TCF7L2 gene variants may affect the suscep-
tibility to T2DM by indirectly altering GLP-1 levels, 
whose gene is transcriptionally regulated by this trans-
cription factor (11). T allele of the rs7903146 SNP is 
associated with enhanced expression of TCF7L2 in hu-
man islets, as well as with impaired insulin secretion, 
incretin effects, and enhanced rate of hepatic glucose 
production (41,42). Moreover, Gaulton and cols. (43) 
suggested that the rs7903146 SNP affects T2DM sus-
ceptibility by altering cis regulation and local chromatin 
structure in islet cells.
Genetic analysis in developing countries can often 
be limited by lack of funding and expertise. Therefore, 
we also standardized a reliable and time-efficient allele-
-specific PCR method for genotyping the rs12255372 
SNP. Although, a typical PCR-RFLP assay is compa-
rable in cost, it requires additional steps of incubation 
and electrophoresis. Moreover, this method does not 
require sequence analysis of PCR products or the costly 
and time consuming high-tech genotyping protocols 
used in previous TCF7L2 association studies. Finally, 
we consider necessary to recommend for the allele-spe-
cific PCR assays used for genotyping the rs12255372 
(this work) and rs7903146 (33) SNPs, that users must 
optimize the PCR conditions, especially template star-
ting amount and the number of cycles. 
In summary, the designed method will enable rese-
archers to carry out genetic polymorphism studies for 
rs12255372 risk factor associated with diverse disea-
ses without the use of expensive instrumentation and 
reagents. Our results replicated the association of the 
rs7903146 polymorphism of TCF7L2 gene with T2DM 
in the Venezuelan population. Although the genotypic 
and allelic frequencies for the TCF7L2 rs12255372 and 
DG10S478 polymorphisms did not differ significantly 
between the patients and controls, the predominance 
of genotypes carrying mutant alleles in T2DM subjects 
cannot be dismissed. Further studies with larger sample 
size and biochemical data for glucose tolerance and me-
asurements on insulin secretion should be conducted in 
Venezuelan population to confirm the putative role of 
this gene in insulin secretion. 
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